Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Orexo Q4 2020, incl. Full Year Report

ZUBSOLV® stable and strong EBIT, despite challenging market due to Covid-19  Q4 2020 highlights · Total net revenues of SEK 159.2 m (238.1 last year, 196.2 m excl. Abstral® EU and US) · Net earnings of SEK -49.6 m (38.9) · EBITDA of SEK 1.0 m (85.8) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 143.1 m (190.5), EBIT of SEK 94.4 m (95.5) · Cash flow from operating activities of SEK -11.2 m (60.2), cash balance of SEK 505.3 m (816.8) · Secured a preferred position for ZUBSOLV® as the only branded product on national commercial and Medicare Part D formularies

SRV Group Plc: Proposals of the Shareholders’ Nomination Board to the Annual General Meeting 2021

SRV GROUP PLC     STOCK EXCHANGE RELEASE     28 JANUARY 2021      09:00 EET SRV Group Plc: Proposals of the Shareholders’ Nomination Board to the Annual General Meeting 2021 SRV Group Plc’s Annual General Meeting 2020 established a Shareholders’ Nomination Board to prepare annually proposals concerning the composition and remuneration of the Board of Directors. SRV Group Plc’s Shareholders’ Nomination Board proposes to the Annual General Meeting of SRV Group Plc that five members will be elected to the Board of Directors. Shareholders’ Nomination Board proposes that present

Statement by the Board of Directors of Recipharm regarding the public offer from Roar BidCo

The Board of Directors unanimously recommends the shareholders and holders of convertible bonds to accept the offer from Roar BidCo. This statement is made by the board of directors of Recipharm AB (publ) (“Recipharm”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the ”Takeover Rules”). The Offer On 14 December 2020, EQT IX, through Roar BidCo AB (the “Offeror”), announced a public offer of SEK 220 per share to the shareholders of Recipharm after having submitted an indicative offer to the board of SEK 196 per share at an initial stage. Today, 28 January 2021, the

Roar BidCo AB announces an increased recommended offer to the shareholders and Holders of Convertible Bonds in Recipharm AB (publ) that cannot be increased

The increased consideration amounts to SEK 232 per share and SEK 1,504,295 per Convertible Bond. On 14 December 2020, EQT IX[1 ]("EQT IX"), through Roar BidCo AB[2][ ]("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares[3] and Convertible Bonds to Roar BidCo for SEK 220 in cash per share and SEK 1,427,010 in cash per SEK 1,000,000 in aggregate principal amount of Convertible Bonds (the "

Recipharm AB publishes report for the fourth quarter and full year 2020

October – December 2020 · Net sales amounted to SEK 2,812 million (1,981), an increase of 42% · EBITA increased by 65% and amounted to SEK 378 million (230) corresponding to an EBITA margin of 13.5% (11.6) · Operating profit (EBIT) amounted to SEK 339 million (117) and was affected by non-recurring items of SEK +54 million (-52) · Profit after tax amounted to SEK 223 million (90) corresponding to a net margin of 7.9% (4.5) · Earnings per share amounted to SEK 2.20 (1.32) before dilution and SEK 2.19 (1.32) after dilution. Core EPS amounted to SEK 1.40 (2.55) · Leverage

BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin’s lymphoma patients

· Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin’s lymphoma patients who have relapsed after treatment with rituximab · Long-lasting complete responses observed in two patients beyond 12 months · Key opinion leader (KOL) call to discuss results today, January 28, at 5.30 p.m. CET (11:30 a.m. ET)   Lund, Sweden – January 28, 2021 – BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-

Notice to convene the Annual General Meeting of Wärtsilä Corporation

Wärtsilä Corporation, stock exchange release, 28 January 2021 at 8.40 am EETNotice to convene the Annual General Meeting of Wärtsilä Corporation Notice is given to the shareholders of Wärtsilä Corporation of the Annual General Meeting to be held on Thursday 4 March 2021 at 3 p.m. EET at the Company’s headquarters at the address Hiililaiturinkuja 2, 00180 Helsinki, Finland. The shareholders of the Company may participate in the meeting and exercise their shareholder rights only by voting in advance and by presenting counterproposals and asking questions in advance. Instructions for

Wärtsilä’s Financial Statements Bulletin January–December 2020

Wärtsilä Corporation, Financial Statements Bulletin January–December 2020, 28 January 2021 at 8:30 a.m. local timeWärtsilä’s Financial Statements Bulletin January–December 2020 This release is a summary of Wärtsilä’s Financial Statements Bulletin January–December 2020. The complete report is attached to this release as a pdf file. It is also available on the company website at www.wartsila.com. 2020 – a year characterised by COVID-19 related uncertainty Highlights of October–December 2020 · Order intake decreased by 28% to EUR 1,118 million (1,555) · Net sales decreased by

Nordic Paper Year-end report January – December 2020

Quarterly results October - December ·Net sales decreased by 9% to SEK 670m (738), excluding currency effects the decrease was 3% ·EBITDA was SEK 144m (65), corresponding to an EBITDA margin of 21.4% (8.8) ·Maintenance stop in Bäckhammar affected the quarterly operating result negatively by SEK 9m (57) ·IPO costs in the quarter was SEK 2m (-) ·Operating profit was SEK 113m (40), corresponding to an operating margin of 16.8% (5.4) ·Net result for the period amounted to SEK 75m (32) ·Cash flow from operating activities was SEK 17m (14) ·

Gränges’ year-end report January–December 2020

Strong fourth quarter concluded a challenging yet productive year Fourth quarter 2020 · The acquisition of Aluminium Konin has been completed and is consolidated from November. · Sales volume increased by 32.6 per cent to 103.3 ktonnes (77.9). Net sales increased to SEK 3,149 million (2,682). Excluding acquisitions sales volume increased by 13.9 per cent and net sales was SEK 2,761 million. · Adjusted operating profit increased to SEK 193 million (144) and adjusted operating profit per tonne was 1.9 kSEK (1.9). Excluding acquisitions, adjusted operating profit increased to SEK

CapMan to publish its 2020 Financial Statements Bulletin on Thursday 4 February 2021

CapMan Plc press release                              28 January 2021 at 8.30 a.m. EET CapMan to publish its 2020 Financial Statements Bulletin on Thursday 4 February 2021 CapMan will publish its 2020 Financial Statements Bulletin on Thursday 4 February 2021 around 8.30 a.m. EET. The company will present the results for the review period over a webcast press conference starting at 9.00 a.m. EET accessible at https://capman.videosync.fi/2020-q4-results. The conference will be held in English. The report and presentation material will be available at CapMan’s website

Elisa’s Financial Statements Release 2020

ELISA FINANCIAL STATEMENT RELEASE 28 JANUARY 2021 AT 8:30 AMFourth quarter 2020 financial highlights · Revenue increased by EUR 11m to EUR 498m, mainly due to growth in telecom and digital services, as well as equipment sales. · Mobile service revenue increased by 0.7 per cent to EUR 209m. · EBITDA grew by EUR 3m to EUR 171m. · Comparable EBIT increased by EUR 3m to EUR 103m. · Comparable cash flow increased by EUR 44m to EUR 99m, mainly due to a change in net working capital and lower capital expenditure. · Mobile post-paid ARPU increased from the previous quarter to

UPM’s growth plans in biofuels progress to the next stage

(UPM, Helsinki, 28 January 2021 at 08:15 EET) – UPM moves forward with biofuels growth plans and starts the basic engineering phase of a next generation biorefinery. The potential biorefinery would have an annual capacity of 500,000 tonnes of high-quality renewable fuels including sustainable jet fuel. The products would significantly reduce carbon footprint in the road transport and aviation, as well as replace fossil raw materials with renewable alternatives in chemicals and bioplastics. “The planned biorefinery would scale up UPM’s successful biofuels business to a new level. At the

Archer Limited: Q4 2020 trading update and 2021 financial outlook

Hamilton, Bermuda (January 28, 2021) Archer will today host an analyst call where we will share our preliminary financials for Q4 2020 and our outlook for 2021. Trading update Q4 2020 Based on preliminary unaudited financials, Archer Limited expects to report the following key financials for Q4 2020: · Revenue of $211 million was up 15% compared to third quarter · EBITDA reported of $19.2 million was up 23% compared to third quarter · EBITDA before exceptional items of $23.3 million · Net interest bearing debt of $504 million · Robust liquidity of $110 million

Interim report for the fourth quarter and full-year 2020

NCC delivers steady progress“NCC’s project portfolio has improved, which is reflected in our earnings. During this quarter, we also took measures to strengthen our industrial operations,” says Tomas Carlsson, President and CEO of NCC. · The contracting business has steady progress. Improved operating profit, healthy orders received and strong order backlog in Building Sweden and Building Nordics. Somewhat lower orders received in Infrastructure due to more early involvement projects and a lower tender outcome · The plan for improved earnings in the Industry business area that was

Understanding how genetic motifs conduct "the music of life"

Our genetic codes control not only which proteins our cells produce, but also – to a great extent – in what quantity. This ground-breaking discovery, applicable to all biological life, was recently made by systems biologists at Chalmers University of Technology, Sweden, using supercomputers and artificial intelligence. Their research, which could also shed new light on the mysteries of cancer, was recently published in the scientific journal Nature Communications. DNA molecules contain instructions for cells for producing various proteins. This has been known since the middle

Invitation to presentation of Orkla’s fourth quarter 2020 results, Thursday 11 February

Orkla will report its fourth quarter 2020 results on Thursday, 11 February 2021 at 7.00 a.m. CET.The quarterly report and the presentation material will be available at this time at: https://investors.orkla.com.The results will be presented in a webcast with Presidet & CEO Jaan Ivar Semlitsch and CFO Harald Ullevoldsæter at 8.00 a.m. CET. As a consequence of the Corona situation, there will not be a physical presentation of the results.The presentation and subsequent Q&A session will be held in English and may be viewed live at https://investors.orkla.com (direct link: https://events.

Year-end announcement 2020

· Highly resilient performance in Q4, despite challenging operating conditions · Credit Management Services positioned for growth with strong sales and record pipeline · Strong cash returns in recovering Strategic Markets · Impressive performance in Portfolio Investments, investment levels at replenishment rate with attractive returns · Accelerating towards ONE IntrumFourth quarter, October-December 2020 · Cash Revenues amounted to SEK 5,601 M (5,751).  · Cash EBITDA amounted to SEK 3,124 M (3,063). · Cash EBIT amounted to SEK 1,523 M (1,419).  · Cash RoIC was 8.7

Michael Ladurner appointed Chief Financial Officer of Intrum

Michael Ladurner has been appointed Chief Financial Officer (CFO) of Intrum. Ladurner has been acting CFO since October 2020. He joined the Group in 2016 and has had roles as Business Development Director for Portfolio Investments and Group Strategy and Analytics Director. Michael Ladurner takes on the CFO role from today, 28 January 2021. He will be reporting directly to President & CEO Anders Engdahl and be a part of the Group Management Team. For further information, please contact:Anna Fall, Chief Brand & Communications Officer+46 (0)709 96 98 21anna.fall@intrum.com This

Year-end Report January – December 2020

“TF Bank’s loan portfolio increased by 8% in local currencies during the fourth quarter. Nordic risk and the credit card initiative in Germany have been prioritised. For consumer loans in Norway and Finland, we soon intend to sign new agreements for continuing sales of past due loans, which provides comfort and predictability for the future. Overall, TF Bank is well positioned to continue expanding during 2021.” – Mattias Carlsson, CEOOctober – December 2020 compared with October – December 2019 · The loan portfolio amounted to SEK 7,922 million, the increase in local currencies was 8 %

Kungsleden divests residential building rights in Västerås

Kungsleden has signed an agreement with JM AB to divest the Västerås Isolatorn 12 property with future residential building rights at a price, before deductions, of SEK 4,100/sq.m. GTA.The property currently comprises approximately 12,000 sq.m. of vacant industrial buildings. Kungsleden has successfully pursued a zoning plan process to transform the property into an attractive residential area. The new zoning plan, which is under review, would allow residential housing of about 36,000 sq.m. GTA and a preschool of 1,000 sq.m. GTA. The purchaser assumes responsibility for soil remediation and

JM acquiring building rights for development of 400 residential units in Västerås

JM has signed an agreement with Kungsleden AB to acquire the property Västerås Isolatorn 12. The deal is worth approximately SEK 120 million. Occupancy and payment will take place after the detailed plan has gained legal force, which is estimated to occur in Q2 2021.The detailed plan is expected to allow the development of around 400 residential units and potentially a preschool. This acquisition gives JM access to an attractive development area in Emaus, Västerås. The acquisition will be reported within the JM Residential Sweden business segment, East Region, in Q2 2021. “The property

2020 Corruption Perceptions Index reveals widespread corruption is weakening COVID-19 response, threatening global recovery

The 2020 Corruption Perceptions Index  (CPI) released today by Transparency International reveals that persistent corruption is undermining health care systems and contributing to democratic backsliding amid the COVID-19 pandemic.Countries that perform well on the index invest more in health care, are better able to provide universal health coverage and are less likely to violate democratic norms and institutions or the rule of law.   “COVID-19 is not just a health and economic crisis. It is a corruption crisis. And one that we are currently failing to

There are no items matching the current filter
There are no more items matching the current filter
Back to top